Acute myeloid leukemia (AML) with MLL gene rearrangements (MLLmut) is often associated with M5 or M4 FAB subtypes, is frequent in infants and in patients with secondary leukemia following treatment with DNA topoisomerase-II inhibitors. 1 MLLmut are predictive of a poor clinical outcome in AML, even if the outcome of patients with t(9;11) is more favorable than that with other MLLmut. The MLL gene (11q23) is involved in about 60 different translocations and about 30 partner genes have been identified. The most common translocation in AML is t(9;11)(p22;q23) giving rise to MLL-AF9. 1 The HDAC inhibitor (HDACi) valproic acid (VPA) induces tumor-selective apoptosis through activation of the death receptor pathway AML with PML-RAR-alpha or AML1-ETO. 2 The present study investigates the effects of the inhibition of HDACs by VPA (with/without ATRA) in MLL-AF9 AML-M5 cell lines (THP-1, Mono-Mac-6 (MM6) and MOLM-13) and leukaemic blasts from AML-M5 patients with MLLmut or MLL wild type (MLLwt) (clinical data in Supplementary Information). A normal bone marrow sample was obtained from a healthy donor. Clinical AML peripheral blood and normal bone marrow samples were obtained following informed consent as per institutional research ethics board guidelines.
Valproic acid consistently decreased cell viability ( Figure 1a treatment by VPA in the three MLL-AF9 AML-M5 cell lines, MLL-AF9 transcript levels resulted either unaltered or increased (Figure 1d) .
In order to clarify the molecular mechanisms of HDAC inhibition by VPA on MLL-AF9 AML-M5 cells, a time course experiment (6, 24 and 48 h) was performed to explore the global changes in gene expression induced by VPA and/or ATRA in THP-1 cells.
A small number of genes were significantly affected by VPA ( Supplementary Information, Figure 2 ). By contrast, VPA with ATRA, while causing changes in a limited number of genes after 6 and 24 h, led to a consistent increase in the genes that changed after 48 h (the complete list of genes is in the Supplementary Information).
After 6 h of treatment, a greater number of genes were changed by VPA than by treatment with ATRA or VPA plus ATRA. As expected from VPA as a HDACi, most of the genes were upregulated ( Supplementary Information, Figure 2a ). The number of genes changed by VPA remained similar after 24 and 48 h. By contrast, VPA with ATRA induced a progressive increase in the number of genes changed (Supplementary Information, Figure 2a ).
Each treatment can be distinguished by a specific number of probe sets that changed (409 for VPA, 577 for ATRA and 957 for VPA plus ATRA) ( Supplementary Information, Figure 2b ).
To shed light on the biological meaning of microarrays data, we categorized genes using biological annotations and then determined the significance of the categories that changed. In line with the restricted number of genes affected by VPA in THP-1 cells, no biological process was significantly modified. By contrast, after 48 h of treatment with VPA plus ATRA, many biological processes were involved and the category of cell proliferation was the most affected, mainly involving downregulation of cell-growth promoting gene ( Supplementary  Information, Figure 3) .
To identify key onco-suppressor genes directly related to HDAC inhibition by VPA, we selected the genes increased after 6 h of treatment. After 6 h, VPA induced high espression only in a few genes with potential onco-suppressor activity, including p21 and cyclin G2 (CG2), 3 involved in G1 cell-cycle arrest. Since G1 cell-cycle arrest was the main biological response emerged during microarray analisys in THP-1 cells, VPA induction of p21 and CG2 was further analyzed.
CG2, together with cyclin G1 (CG1), belongs to the G cyclin family with the atypical cyclin activity associated with induction of G1 cell-cycle arrest.
Induction of p21 and CG2 was confirmed by real time RT-PCR in the three MLL-AF9 positive cell lines and in the MLLmut AML-M5 (Figure 2a ). In the 2 days of monitoring, the increased mRNA expression of p21 was maintained or increased in the three MLL-AF9 cell lines and in the MLLmut AML-M5 blasts, and after 24 h was confirmed at the protein level in THP-1 and MOLM-13 cells (Figure 2b ). The strong CG2 induction recorded after 6 h progressively decreased (except in MLLmut AML-M5 blasts) (Figure 2a ) and no differences in the protein levels were found at 24 h in THP-1 and MOLM-13 cells (Figure 2b ). Induction of p21 and CG2. (a) Real-time RT-PCR results of p21 and CG2 mRNAs treated or not with valproic acid (VPA) (V) and/or ATRA (A) for 6, 24 and 48 h. Triplicate real-time PCR was performed for p21, CG2, and -actin using the TaqMan assays-on-demand (Applied Biosystem, Foster City, USA) as described ( Supplementary Information, reference 1) . Each square represents the difference between the control and treated samples. The squares filled with diagonal lines are not evaluable time points. (b) Western blot analysis of p21 and CG2. The analysis was performed as described ( Supplementary Information, reference 1 ). For CG2, 1:800 goat polyclonal antibody (Santa Cruz, CA) was used. (c) Induction of histone acetylation in p21 and CG2 promoters in THP-1 by VPA. Acetylation of histones H3 and H4 was measured by chromatin immunoprecipitation (ChIP) and real-time PCR in four genomic regions. MyoD and a consensus repeat of chromosome 2 alpha-satellite DNA (sat) were used as negative controls of acetylation. Graphs represent mean DNA fragment recoveries with specific antibodies indicated above 7s.e. White bars -control cells; grey bars -cells treated with VPA for 6 h. Recovery values for non-immune IgG were from 0 to 0.06%. Agarose gels for products of PCR interrupted in exponential amplification phase are shown on the right. ChIP-recovered DNA samples, two input DNA standards of indicated concentrations and TE (PCR negative control) were run in parallel. For the antibodies and DNA primers used see Supplementary Information. Chromatin preparation was as described ( Supplementary Information, reference 2) . 2-4% of total ChIP-recovered DNA was used in each PCR. Quantitative PCR was performed as described (Supplementary Information, reference 2) with an annealing temperature of 571C for sat, 651C for MyoD and 601C for p21 and CG2.
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Treatment with VPA plus ATRA increased the levels of p21 induction in the three MLL-AF9 AML-M5 cell lines and in MLLmut AML-M5 blast cells, whereas it produced either no effect or a decrease in the levels of CG2 induction (Figure 2a ). ATRA by itself had no effect (Figure 2a) .
Analysis of normal bone marrow (nBM) cells revealed that VPA-induction of p21 was tumor-specific, while CG2 was induced also in nBM cells (Figure 2a) . In MLLwt AML-M5 blast cells, induction of p21 was absent, whereas CG2 was activated.
Analysis of AML-M2 and -M3 cells, respectively, expressing AML1-ETO and PML-RAR-alpha, indicated that the induction of p21 and CG2 by VPA was not specific of MLLmut AMLs (Figure 2a) .
VPA-induced histone acetylation of p21 and CG2 promoters indicating that their induction was directly related to HDAC inhibition (Figure 2c) .
To evaluate the direct role exerted by the activation of p21 and CG2 expression in the VPA-induced G1 cell-cycle arrest, knockdown of p21 or CG2 was performed using their specific small interfering RNAs (siRNAs) during VPA or VPA plus ATRA treatment in THP-1 cells. Results of the real time PCRs for p21 and CG2 expression were compared to the scrambled siRNA without treatment and are as follows: treatment with VPA plus the scrambled siRNA increased the expression of p21 by 10.7-and 4-fold (after 24 and 48 h, respectively), whereas treatment with VPA plus the two siRNAs specific for p21 increased the expression of p21 by 4.5-and 1.4-fold (after 24 and 48 h, respectively) ( Figure 3a) ; treatment with VPA plus the scrambled siRNA increased the expression of CG2 by 6.5-and 1.5-fold (after 24 and 48 h, respectively) as compared to the scrambled without VPA, whereas treatment with VPA plus the two siRNAs specific for CG2 increased the expression of CG2 by 0.7-and 0.4-fold (after 24 and 48 h, respectively) (Figure 3a) . Variations in fold changes of gene expression within the interval of 72 were not considered significant.
The results of cell viability demonstrated that p21 acts as a key regulator being directly related to 45% of the VPA-induced cell growth inhibition, while induction of CG2 has no effect in the VPA-induced cell-growth inhibition in MLL-AF9 AML cells (Figure 3b) . The results obtained by the knockdown assay of p21 or CG2, performed during combined treatment with VPA and ATRA in THP-1 cells, did not substantially differ from those obtained for VPA as a single agent.
Summarizing, we demonstrated that VPA induced strong cellgrowth inhibition in MLL-AF9 AML-M5 cells (THP-1, MM6 and MOLM-13) and MLLmut AML-M5 blasts. Cell cycle analysis in THP-1 cells showed that VPA induced a G1 phase arrest. 
Apoptosis was induced by VPA in all the three MLL-AF9 AML-M5 cell lines (THP-1, MM6 and MOLM-13).
Combined treatment with all-trans-retinoic-acid (ATRA) did not substantially improve these effects, and only marginally supports the suggested combined treatment with HDACi and ATRA in other AML types. 4 Since targeted downregulation of MLL-AF9 induces strong cell-growth inhibition and apoptosis, 5, 6 our results indicate that HDACi by VPA can overcome the resistance conferred by MLL-AF9 in MLL-AF9 AML-M5 cells, even in the presence of an increased expression of MLL-AF9.
p21 and CG2 emerged as the main cell-cycle inhibitory genes upregulated by VPA in MLL-AF9 AML. CG2 induction is p53-independent. 3 Induction of p21 by VPA was also p53-independent as THP-1 is p53-absent. 7 As in AML with MLL fusion proteins (including MLL-AF9) p53 is functionally inactivated leading to a lost response to DNA damage, 8 our data indicate that VPA could activate a p53-independent G1 cell-cycle arrest and apoptosis in MLL-mut AML.
Finally, we demonstrated not only that p21 can be used as a tumor-specific marker of VPA treatment in MLLmut AML but that it also plays an active and key role in G1 cell-cycle arrest in AML-M5 expressing MLL-AF9. By contrast, the VPA-induced CG2 is not tumor-specific and has no relevant role in G1 cellcycle arrest.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) ArgBP2, encoding a negative regulator of ABL, is fused to MLL in a case of infant M5 acute myeloid leukemia involving 4q35 and 11q23 Children with acute myeloid leukemia (AML) in Italy have a probability of event-free survival of 53% at 5 years.
1 Acute myeloid leukemia associated with rearrangements involving the MLL gene (translocations, duplications, inversions, deletions) are frequently found in infants and in patients with secondary leukemias following treatment with DNA topoisomerase-II inhibitors, and are most often associated with the AML-M5 or -M4 FAB subtypes. 2 The MLL gene (also called ALL-1 or HRX), located at 11q23, is involved in over 60 different translocations leading to gene fusion and over 30 partner genes have so far been cloned and partially characterized. 2 The most common translocation is the t(9;11)(p22;q23) giving rise to the MLL-AF9 fusion gene, while other recurring translocations are the t(11;19)(q23;p13.3) and the t(11;19)(q23;p13.1), producing, respectively, the MLL-ENL and MLL-ELL oncogenes. Several studies have demonstrated that the transcriptional effector functions of the MLL fusion partners are essential for leukemogenesis; however, there are few common characteristics among these partner proteins that can clarify their role in leukemogenesis.
